A phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma

Japanese Journal of Clinical Oncology

Volumn 33, Issue 11, 2003, Pages 570-573

  Ishii, Hiroshi ^a   Furuse, Junji ^a   Nagase, Michitaka ^a   Maru, Yasushi ^a,b   Yoshino, Masahiro ^a   Hayashi, Takayuki ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Chiba Social Insurance Hospital   (Japan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Liver neoplasms; Phase I clinical trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; DRUG DERIVATIVE; IODINATED POPPYSEED OIL; MALEIC ANHYDRIDE; POLY(MALEIC ACID STYRENE)NEOCARZINOSTATIN; POLY(MALEIC ACID-STYRENE)NEOCARZINOSTATIN; POLYSTYRENE DERIVATIVE; ZINOSTATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTERY CATHETERIZATION; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BED REST; BLOOD TOXICITY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEPATIC ARTERY; HEPATIC ENCEPHALOPATHY; HUMAN; HYDRATION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MALEIC ANHYDRIDES; MIDDLE AGED; POLYSTYRENES; ZINOSTATIN;

EID: 1342268243     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg106     Document Type: Article

References (23)

1. Maeda H. Recent advances in research on SMANCS. Gan To Kagaku Ryoho 1998;25 Suppl 1:1-9 (in Japanese).
2. Toge T, Jinushi K, Sawamura A, Matsuki K. Study on the intra-tumor tissue concentration of zinostatin stimalamer in the liver following intraarterial injection of zinostatin stimalamer (YM881) suspension. Gan To Kagaku Ryoho 1991;18:1677-80 (in Japanese).
3. Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881. Gan To Kagaku Ryoho 1991;18:1665-75 (in Japanese).
4. Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 1998;5:276-83.
5. Ikeda K, Saitoh S, Suzuki Y, Tsubota A, Koida I, Kobayashi M, et al. Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer - a pilot study. J Gastroenterol 1997;32:513-20.
6. Abe S, Otsuki M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Carr Med Chem Anti-Cancer Agents 2002;2: 715-26.
7. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, et al. Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma. J Gastroenterol 2000;35:353-60.
8. Abe S, Yamasaki T, Nakano K, Yoshikawa I, Tabaru A, Otsuki M. Multiple hepatic infarction after transcatheter arterial infusion with SMANCS. J Gastroenterol 2001;36:415-21.
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication 48. Geneva, World Health Organization, 1979.
10. National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0, April 30, 1999. http://ctep.info.nih.gov/reporting/ctc.html
11. Sobin L, Wittekind C. TNM classification of malignant turnouts, 5th edition. John Wiley & Sons, New York, NY 1997.
12. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28:751-5.
13. Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, et al. A prospective randomized trial of the preventive effect of preoperative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996;87:206-11.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Barcelona Liver Cancer Group. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-9.
15. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterol 1988;94:453-6.
16. Pelletier G, Roche A, Ink O, Anciaux ML, Derby S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
17. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with Lipiodol chemoembolization: A multicenter randomized trial. J Hepatol 1998;29:129-34.
18. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83.
19. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Eng J Med 1995;332:1256-61.
20. Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, et al. Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40.
21. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: Treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345-51.
22. Yoshikawa M, Saisho H, Ebara M, Iijima T, lwama S, Endo F, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33 Suppl:S149-52.
23. Abe S, Okubo Y, Ejiri Y, Kume K, Otsuki M. Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma. J Gastroenterol 2000;35:28-33.